Summit Global Investments increased its stake in Dr. Reddy's Laboratories by 13.4% in Q4, and the company reported Q4 EPS of $0.99, exceeding estimates.

Summit Global Investments increased its stake in Dr. Reddy's Laboratories (NYSE: RDY) by 13.4% in Q4, owning 35,348 shares. Other investors also boosted their stakes, with Allspring Global Investments increasing its stake by 8.9%. The pharmaceutical company reported Q4 EPS of $0.99, exceeding estimates by $0.11. Dr. Reddy's operates in Global Generics, Pharmaceutical Services and Active Ingredients, and Others segments.

May 04, 2024
3 Articles